APPLICATION
ANDA201890
TYPE
ANDA
ORIGINAL APPROVAL
2017-04-26
LATEST ACTION
2024-05-30
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued
Products
EZETIMIBE AND SIMVASTATINDiscontinued
EZETIMIBE 10MG, SIMVASTATIN 40MG · TABLET · ORAL
EZETIMIBE AND SIMVASTATINDiscontinued
EZETIMIBE 10MG, SIMVASTATIN 10MG · TABLET · ORAL
EZETIMIBE AND SIMVASTATINDiscontinued
EZETIMIBE 10MG, SIMVASTATIN 80MG · TABLET · ORAL
EZETIMIBE AND SIMVASTATINDiscontinued
EZETIMIBE 10MG, SIMVASTATIN 20MG · TABLET · ORAL
Approval history
2024-05-30Labeling · Supplement 12 · standardAP
2024-05-30Labeling · Supplement 11 · standardAP
2021-02-23Labeling · Supplement 10 · standardAP
2020-01-29Labeling · Supplement 8 · standardAP
2020-01-29Labeling · Supplement 9 · standardAP
2019-04-02Labeling · Supplement 5 · standardAP
2017-04-26Not Applicable · OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.